• Grifols Q1 2026 earnings call featured CEO Nacho Abia, CFO Rahul Srinivasan, President Biopharma Roland Wandeler, VP IR and Sustainability Daniel Segarra.
• Q1 revenue reached EUR 1.7 billion, up 3.3% at constant currency; adjusted EBITDA was EUR 381 million with 22.4% margin; net leverage held at 4.3x.
• Management reiterated 2026 targets for adjusted EBITDA margin of at least 25% plus free cash flow of EUR 500 million to EUR 575 million; noted plasma-derived therapies were exempted from US tariffs under Section 232.
• Egypt plasma platform positioned as major margin lever, with about 1,000,000 liters targeted in 2026 scaling to 3,000,000 liters by 2029; strategy aims to cut cost per liter, reduce reliance on exporting higher-cost US plasma to lower-priced markets.
• Executives declined to discuss rationale or timing for potential US IPO of portion of US Biopharma business; CFO said move was not driven by balance sheet stress and framed it as an option to maximize shareholder value.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grifols SA published the original content used to generate this news brief on May 08, 2026, and is solely responsible for the information contained therein.